Journal article

Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes

Abstract:: Importance Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs would require large outcome trials. Human genetics studies can help prioritize or deprioritize these resource-demanding endeavors. Objective To investigate the independent and combined assoc... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Lotta, L. A., Stewart, I. D., Sharp, S. J., Day, F. R., Burgess, S., Luan, J., Bowker, N., Cai, L., Li, C., Wittemans, L. B. L., Kerrison, N. D., Khaw, K.-T., McCarthy, M. I., O'Rahilly, S., Scott, R. A., Savage, D. B., Perry, J. R. B., Langenberg, C., & Wareham, N. J. (2018). Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes. JAMA Cardiology, 3(10), 957–966.

MLA Style

Lotta, LA, et al. “Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles with Risk of Coronary Disease and Type 2 Diabetes.” JAMA Cardiology, vol. 3, no. 10, 2018, pp. 957–66.

Chicago Style

Lotta, LA, ID Stewart, SJ Sharp, et al. 2018. “Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles with Risk of Coronary Disease and Type 2 Diabetes.” JAMA Cardiology 3 (10): 957–66.
Print

Access Document

Files:: hoi180042supp1_prod.pdf

(Preview, Version of record, pdf, 312.3KB, Terms of use)

jamacardiology_lotta_2018_oi_180042.pdf

(Preview, Version of record, pdf, 585.8KB, Terms of use)

Publisher copy:: 10.1001/jamacardio.2018.2866

Authors

+ Lotta, LA More by this author

Role:: Author

+ Stewart, ID More by this author

Role:: Author

+ Sharp, SJ More by this author

Role:: Author

+ Day, FR More by this author

Role:: Author

+ Burgess, S More by this author

Role:: Author

More authors...

+ Royal Society More from this funder

Grant:: 204623/Z/16/Z

+ Wellcome Trust More from this funder

Grant:: 100574/Z/12/Z

+ Sixth Framework Programme More from this funder

Grant:: LSHM_CT_2006_037197

+ Medical Research Council More from this funder

Grant:: MC_UU_12012/5

+ European Federation of Pharmaceutical Industries and Associations More from this funder

More funders...

Publisher:: American Medical Association
Journal:: JAMA Cardiology More from this journal
Volume:: 3
Issue:: 10
Pages:: 957-966
Publication date:: 2018-09-19
Acceptance date:: 2018-07-26
DOI:: 10.1001/jamacardio.2018.2866
EISSN:: 2380-6591
ISSN:: 2380-6583

Pubs id:: pubs:891825
UUID:: uuid:c6670bf2-8f35-4db6-becd-c7bf2a82704b
Local pid:: pubs:891825
Source identifiers:: 891825
Deposit date:: 2018-07-31
ARK identifier:: ark:/29072/ora_c6670bf28f354db6becdc7bf2a82704b

Terms of use

Copyright holder:: Lotta et al
Copyright date:: 2018
Notes:: © 2018 Lotta LA et al. This is an open access article distributed under the terms of the CC-BY License.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP